You are here

P&T March 2013

Features

Letter to the Editor
Editorial
Treatment-resistant depression is extremely common—but does that mean there is no place for antidepressants?
Health Care & Law
New Features in 2013

Among the health care changes this year: revenues to hospitals will be lower, payments to physicians will be modified, and more patients will be covered by Medicaid.

Composition of Formularies Is a Point of Contention

it is unclear how the final rule on “clinically appropriate” and “medically necessary” drugs will apply to hospital formularies and Part B drugs given in the doctor’s office.

Pharmacovigilance Forum
Are Your Patients at Risk?

The author presents 4 case histories of patients who experienced angioedema after treatment with various ACE inhibitors in what some have called a “silent epidemic.”

Pharmacovigilance Forum
Three agents have recently been approved to reduce the risk of stroke and embolism, and one agent is in phase 3 trials. These drugs cause less serious bleeding and are simpler to manage, compared with warfarin, but they are not without their risks.

Departments

Medication Errors
Borrowing and lending drugs is a dangerous business.
Prescription: Washington
The DHS pushes to expand e-prescribing. Pharmacy groups push back.

FDA approvals, drug indications, and updates

Bedaquiline for multiresistant pulmonary tuberculosis; Flublok influenza vaccine; and Octaplas for coagulation factor deficiency

Drug Forecast
Linaclotide (Linzess) for irritable bowel syndrome with constipation and for chronic idiopathic constipation